Abstract. ·-fetoprotein-producing adenocarcinoma of the digestive organs (APAD) is known to show a poor prognosis. To clarify the characteristics of chemoresistance in APAD, three proteins of fluoropyrimidine chemotherapy association [dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP) and thymidylate synthase (TS)] and one protein of cisplatin association [metallothionein (MT)] were immunohistochemically evaluated. Tissue samples were taken from 12 AFP-positive gastric cancers and 94 AFP-negative gastric cancers. Four AFP-positive cancer xenografts (one colonic, two pancreatic, and one biliary tract) and 17 AFP-negative cancer xenografts were also examined. In gastric cancers, high expression of TP was observed in 30% of AFP-negative tumors but in none of AFP-positive tumors (p=0.03). High expression of MT was found in 30% of AFP-negative tumors but in only one of the AFP-positive tumors. The TP-low and MT-low phenotype was noted in 92% of AFP-positive tumors and in 46% of AFP-negative tumors (p=0.004). None of the AFPpositive cancer xenografts revealed high TP expression and only one showed high MT expression. In the cellular level, TP and MT were scarcely co-expressed with AFP in either gastric cancer or xenograft series, using double immunostaining and serial sectioning techniques. There were no significant differences in the expression of DPD and TS between AFP-positive group and -negative group. However, DPD was frequently co-expressed with AFP in poorly differentiated medullary areas of the AFP-positive gastric cancers. The data presented herein suggest that APAD should be sensitive to cisplatin, but resistant to capecitabine and 5'-deoxyfluorouridine, fluoropyrimidines which are converted to 5-fluorouracil by TP. S-1, a fluoropyrimidine containing a strong DPD inhibitor, may be effective for AFP-positive gastric cancers with poorly differentiated medullary growth pattern.
Introduction
·-fetoprotein (AFP) is an oncofetal protein produced by the fetal hepatocytes, yolk sac cells and some fetal gastrointestinal cells (1) . AFP has been used clinically as a tumor marker of hepatocellular carcinomas (2) and germ cell tumors (3) . In addition, elevated levels of serum AFP have been reported in patients with adenocarcinomas of the digestive organs (APAD), such as the stomach (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , colon (15) , pancreas (16) and gallbladder (17) . APAD has been associated with a poor prognosis because of frequent hematogenous metastasis to the liver (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . To develop effective therapy for APAD, a better understanding of the characteristics of APAD at the cellular and molecular levels is important.
Fluoropyrimidine-metabolizing enzymes are potentially important in regulating cellular sensitivity to fluoropyrimidines [5-fluorouracil (5-FU) and its prodrugs], which are the most widely used drugs for the treatment of solid cancers. The anticancer effects primarily depend on intratumoral levels of enzymes metabolizing the drugs (18) . Dihydropyrimidine dehydrogenase (DPD) is a rate-limiting enzyme for degrading 5-FU in the liver and other tissues, and a high level of DPD in tumor cells accelerates inactivation of 5-FU. Significant correlations between high expression levels of DPD and fluoropyrimidine resistance or poor prognosis have been described in several types of cancer (19) (20) (21) (22) .
Thymidylate synthase (TS) is the target enzyme of 5-FU, and the inhibition of TS activity is the principal mechanism of cytotoxicity. Several investigators have reported the clinical relevance of high TS expression as a predictor of the resistance to fluoropyrimidine-based chemotherapy (19, (23) (24) (25) (26) .
Expression of chemoresistance-related proteins in ·-fetoprotein-producing adenocarcinoma of the digestive organs
We recently demonstrated that high expression of TS was a predictor of the resistance to neoadjuvant chemotherapy with fluoropyrimidines (27) , and was an important predictor of unfavorable recurrence-free interval and overall survival for colorectal cancer patients treated with fluoropyrimidine-based adjuvant chemotherapy (28) . Thymidine phosphorylase (TP) functions not only as an angiogenesis-inducing factor but also as a metabolic enzyme for 5-FU prodrugs, N 4 -pentyloxycarbonyl deoxyfluorocytidine (capecitabine) and 5'-deoxyfluorouridine (5'-DFUR) (18) . Immunohistochemical studies have shown that gastric and breast cancers expressing high levels of TP respond to 5'-DFUR-based regimens, resulting in a favorable survival of patients (29) (30) (31) .
Metallothionein (MT) is a cysteine-rich protein with a high affinity for heavy metal ions such as zinc and cadmium, and overexpression of MT is associated with the resistance to cisplatin and radiation treatment (32, 33) .
In the present study, to understand the characteristics of APAD from a viewpoint of chemotherapy, we analyzed the expression of a panel of chemoresistance-related proteins (fluoropyrimidine-related DPD, TS and TP, and cisplatinrelated MT) in gastric cancer tissues, and xenografts derived from adenocarcinomas of the digestive organs. Our results suggested that APAD should be sensitive to cisplatin but resistant to capecitabine and 5'-DFUR owing to low expression of MT and TP, respectively.
Materials and methods

Gastric cancer tissues. Between 2000 and 2004, in Fujita
Health University Hospital, Toyoake, and Higashi-Yamato Hospital, Higashi-Yamato, 12 gastric cancers were diagnosed as AFP-positive. AFP was immunohistochemically detected in the resected specimens by the universal immuno-peroxidase polymer method, as described below. For comparison, 94 AFPnegative gastric cancers were also examined. All tissue samples were fixed in 10% formalin and embedded in paraffin.
Cancer xenografts. Seven gastric cancer cell lines (AZ-521, MKN-45, SC-2, SC-4, 4-1ST, ST-40 and TMK-1), five colonic cancer cell lines (COL-1, Co-3, HCT-15, KM12C and KM20C), six pancreatic cancer cell lines (AsPC-1, BxPC-3, MIAPaCa-2, PAN-3, PAN-4 and PAN-12), and three biliary tract cancer cell lines (BD-01, OCUG-1 and TGB14TKB) were used in the present study. AZ-521 and MKN-45 were purchased from JCRB (Osaka, Japan). HCT-15, AsPC-1, BxPC-3 and MIAPaCa-2 were obtained from ATCC (VA, USA). KM12C and KM20C were kindly provided by Dr K. Morikawa (Iwamizawa Worker's Compensation Hospital, Hokkaido, Japan). TMK-1 was kindly provided by National Cancer Center (Tokyo, Japan). OCUG-1 was purchased from Human Science Research Resources Bank (Osaka, Japan). TGBC14 TKB was obtained from Riken Bioresource Center (Ibaraki, Japan). Other cell lines were established at the Central Institute for Experimental Animals (Kawasaki, Japan). Cells were subcutaneously transplanted into nude mice. When the tumor volume reached 100 mm 3 , the mice were sacrificed, and tumors were fixed in 10% buffered formalin and embedded in paraffin wax. Animal experiments were carried out in accordance with the Guidelines for the Welfare of Animals in Experimental Neoplasia.
Immunohistochemistry. Serial sections, 3 μm-thick, were cut and mounted on aminopropyltriethoxysilane-coated glass slides. The sections were deparaffinized with xylene and rehydrated with graded alcohols. Endogenous peroxidase was inactivated by 0.03% hydrogen peroxide in methanol for 30 min. For the markers other than AFP and TP, heatinduced antigen retrieval was applied using a pressure cooker (Delicio 6L; T-FAL, Rumily, France) for 10 min. Optimal soaking solutions were selected for the respective markers, determined by preliminary experiments: 10 mM citrate buffer, pH 7.0 for MT, and 1 mM ethylenediaminetetraacetic acid solution, pH 8.0 for DPD and TS. After pressure cooking, the sections were left at room temperature for cooling in the soaking solution for 30 min. The sections were then incubated with the primary antibody, which reacts specifically with AFP (rabbit polyclonal, 1: 500 dilution, Dako, CA, USA), DPD (rabbit polyclonal, 1: 1000 dilution, Taiho Pharmaceutical, Tokushima, Japan), TP (mouse monoclonal, clone 2A4P4, 1: 1000 dilution, Taiho Pharmaceutical), TS (rabbit polyclonal, 1: 200 dilution, Taiho Pharmaceutical) or MT (mouse monoclonal, clone E9, 1: 1000 dilution; Dako), overnight at room temperature. Histofine ® Simple Stain MAX-PO (Nichirei, Tokyo, Japan), employing the universal immunoperoxidase polymer method, was utilized as a second-layer reagent. The reaction products were visualized in 50 mg/dl 3,3'-diaminobenzidine tetrahydrochloride solution containing 0.003% hydrogen peroxide. Negative control studies were performed without applying the primary antibodies. As a positive control, sections known to be stained positively were included in each run.
Co-expression of AFP and chemoresistance-related proteins was evaluated for seven representative tumors (four gastric cancers, one colonic cancer xenograft and two pancreatic cancer xenografts) in which >5% tumor cells were positive for AFP. The double immunostaining was performed, employing the universal immuno-alkaline phosphatase polymer method. The sections were incubated with anti-AFP polyclonal antibody overnight at room temperature. Histofine Simple Stain AP (Nichirei) was utilized as a second-layer reagent. Alkaline phosphatase activity was visualized in BCIP/NBT solution (one part of 5-bromo-4-chloro-3-indolyl phosphate solution, one part of nitroblue tetrazorium solution, and 200 parts of 0.1 M Tris buffer, pH 9.5). Dissociation of the antigenantibody complexes was then performed by hydrated heating, which also functions as antigen retrieval sequence, in the optimal soaking solutions for DPD, TS or MT immunostaining as previously described. The sections were incubated with anti-DPD, TS, TP or MT antibody overnight at room temperature. After incubation with Histofine Simple Stain AP, the enzyme reaction was developed with Dako ® Fuchsin+ SubstrateChromogen System (Dako).
Evaluation of the immunostained sections. The immunostained sections were independently assessed by two investigators (S.K. and M.S.). AFP expression was considered positive if any specific staining was detected. With regard to the chemoresistance-related proteins, the sections were classified into two groups based on the proportion of positively stained tumor cells in the lesion: a low group for tumors which were negative or positive but in <30% of tumor cells, and a high group for tumors which were positive in ≥30% of tumor cells. The double-stained sections were classified into four groups as follows: -, co-expression of AFP and the chemoresistance-related protein is never observed; ±, AFP-positive cells infrequently co-express the chemoresistance-related protein; +, AFP-positive cells occasionally co-express the chemoresistance-related protein; ++, AFP-positive cells frequently co-express the chemoresistance-related protein.
Statistical analysis. The Fisher's exact probability test was used for the assessment of differences between AFP-positive and AFP-negative groups. Statistical significance was set at p<0.05.
Results
Intracellular localization. AFP immunoreactivity was mainly observed as vesicular or granular structures in the cytoplasm, which correspond to rough endoplasmic reticula and Golgi apparati as its localization sites. DPD and MT were consistently localized in the cytoplasm of the cells. Positive staining for TS was observed in the cytoplasm but rarely in the nuclei. TP was expressed in both the cytoplasm and the nuclei. Cancer xenografts. Scattered AFP-positive tumor cells were found in one colonic cancer xenograft (Co-3), two pancreatic cancer xenografts (PAN-12 and AsPC-1), and one biliary tract cancer xenograft (OCUG-09). The colonic cancer xenograft was a well-differentiated adenocarcinoma, and the others were poorly differentiated adenocarcinomas. Table II shows the expression of DPD, TS, TP, and MT in cancer xenografts derived from adenocarcinomas of the digestive organs. High expression of TP was observed in six (35%) of 17 AFPnegative xenografts, while all four AFP-positive xenografts revealed low TP expression (p=0.28). High expression of MT was found in seven (41%) of AFP-negative xenografts but in only one (25%) of AFP-positive xenografts. The expression of DPD or TS did not show statistical difference between AFPpositive and -negative groups. The TP-low and MT-low phenotype was seen in three (75%) of AFP-positive xenografts and five (29%) of AFP-negative xenografts (p=0.25). Table III Table II . Expression of chemoresistance-related proteins in AFP-positive and -negative xenografts derived from adenocarcinoma of the digestive organs.
Co-expression of AFP and chemoresistance-related proteins.
-------------------------------------------------
AFP-positive AFP-negative Expression (n=4) (n=17) p- value  ------------------------------------------------ Table I . Expression of chemoresistance-related proteins in AFP-positive and -negative gastric cancers. 
------------------------------------------------- AFP-positive AFP-negative Expression (n=12) (n=94) p-value ------------------------------------------------- DPD
a Statistically significant.
and DPD was found in the gastric cancer cells with a poorly differentiated medullary pattern but not seen in the other areas of the gastric cancers, nor in the xenografts. Fig. 1 shows representative features of immunostaining for AFP and chemoresistance-related proteins in gastric cancers and a colon cancer xenograft.
Discussion
Patients with APAD have been reported to show a poor prognosis with a high incidence of liver metastasis (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . Thus, an individualized therapeutic regimen for APAD should be established. In the present study, in order to gain better Capecitabine is converted to 5-FU through the intermediate metabolite 5'-DFUR. 5'-DFUR is metabolized to 5-FU by TP, also known as platelet-derived endothelial cell growth factor (17) . Reportedly, expression levels of TP correlate with the tumor sensitivity to capecitabine and 5'-DFUR (29) (30) (31) . In gastric cancers, high expression of TP was observed in 30% of AFP-negative tumors but in none of AFP-positive tumors (p=0.03). Similarly, Koide et al reported that in AFPproducing gastric cancers, TP was not expressed and thus was not involved in angiogenesis (11) . These findings suggest that AFP-positive gastric cancers should be resistant to capecitabine and 5'-DFUR.
DPD is the rate-limiting enzyme in the catabolism of 5-FU (18) . TS, a critical target for fluoropyrimidines, catalyzes the methylation of deoxyuridine monophosphate to deoxythymidine monophosphate, an essential step in DNA biosynthesis (18) . Multiple clinical studies have suggested that overexpression of TS and DPD are closely associated with resistance to fluoropyrimidine-based chemotherapy (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . There were no significant differences in the expression of DPD or TS between AFP-positive gastric and -negative groups.
Histologically, AFP-producing gastric cancer tends to show the poorly differentiated medullary type, characterized by polygonal cells arranged in solid nests or sheets, or the well-differentiated papillary or tubular type with clear cytoplasm (5) . DPD was co-expressed with AFP in the tumor cells in poorly differentiated medullary region of AFP-positive gastric cancers. The result suggests that AFP-positive gastric cancer cells growing with poorly differentiated medullary pattern should be resistant to 5-FU. Chang et al (34) reported that growth of two xenograft tumors, established from AFPproducing gastric cancers with poorly differentiated medullary pattern, was not suppressed by 5-FU. Nagai et al (8) described that the prognosis of AFP-positive gastric cancers with a poorly differentiated medullary pattern was particularly poor. S-1 is a novel fluoropyrimidine consisting of tegafur, 5-chloro-2, 4-dihydroxypyrimidine (CDHP, a strong DPD inhibitor) and potassium oxonate with a molar ratio of 1: 0.4: 1 (18) , and shows an anti-tumor activity against tumors with high DPD activity (35) .
MT is a cysteine-rich protein with a high affinity for heavy metal ions such as zinc and cadmium, and the overexpression of MT is associated with resistance to cisplatin and radiation treatment (32, 33) . High expression of MT was found in 30% of AFP-negative gastric cancers but only one of the AFPpositive gastric cancers, the difference did not show statistical significance (p=0.17). Double immunostaining and serial sections directly demonstrated that most of AFP-positive gastric cancer cells, including medullary growth areas, were negative for MT. Chang et al (34) reported that AFP-producing gastric cancer cell line showed a marked regression of tumor growth after administration of cisplatin. AFP-producing gastric cancers, against which cisplatin-containing regimens were effective, have actually been reported by Japanese clinicians (9, 10, 12, 14) .
In xenograft series, high expression of TP was observed in 35% of AFP-negative tumors, while all of AFP-positive tumors revealed low TP expression. High expression of MT was seen in 41% of AFP-negative xenografts but in only one of the AFP-positive xenografts. The lack of significant difference may reflect the relatively small number of xenografts studied. However, double immunostaining and serial sectioning methods confirmed that AFP-positive tumor cells were negative for TP or MT. Taken together, it is postulated that these AFP-positive adenocarcinoma cells likewise may show Table III . Co-expression of chemoresistance-related protein in AFP-positive tumor cells in adenocarcinoma of the digestive organs. 
----------------------------------------------------------------------------------------------------
a All tumor cells are negative for the chemoresistance-related protein. Por, poorly differentiated adenocarcinoma; med, medullary growth pattern; mod, moderately differentiated adenocarcinoma; wel, well differentiated adenocarcinoma; pap, papillary adenocarcinoma; AFPpositive tumor cells co-express the chemoresistance-related protein, frequently (++), occasionally (+), infrequently (±), or never (-).
-----------------------------------------------------------------------------------------------------
resistance to capecitabine and 5'-DFUR and the sensitivity to cisplatin. There was no significant relationship between AFP positivity, and the expression of DPD or TS.
In conclusion, the data presented herein suggest that APAD should be sensitive to cisplatin but resistant to capecitabine and 5'-DFUR owing to low expression of MT and TP, respectively. It is possible that S-1 is effective in AFP-positive gastric cancers with a poorly differentiated medullary growth pattern. To our knowledge, this is the first study to perform simultaneous evaluation of immunohistochemical expression of DPD, TS, TP and MT in relation to AFP expression in adenocarcinomas of the digestive organs. Although the findings were based on the retrospective analysis of a limited number of tumors, we believe the data have relevant clinical implications. Prospective and retrospective clinicopathologic trials with a large sample size are required to confirm our results.
